The Superior Court of Justice of the Canadian Province of Ontario approved the sale of Transition Therapeutics Inc. of Toronto to OPKO Health Inc. of Miami on Aug. 29. The deal was for $60 million to be paid in the form of 6.4 million shares of OPKO common stock distributed to Transition shareholders in exchange for their shares of Transition common stock.
Dr. Phillip Frost, chairman and CEO of OPKO, and his counterpart at Transition, Dr. Tony Cruz, reached an agreement in early May. That was when a team of Greenberg Traurig attorneys went to work, led by Robert Grossman and Joshua Samek. Both are based in Miami.
